Search the Newsreel

Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results

Oramed: Q2 Earnings Snapshot

Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit

Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Oramed Pharmaceuticals Inc (ORMP), noting that no specific earnings forecast score is currently available, although the industry average is 8.10. It highlights an average price target of $3.25 based on zero analyst ratings, indicating a potential 40.13% …

Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday

Oramed Pharmaceuticals (ORMP) is expected to release its Q2 2026 earnings after market close on Thursday, August 13th, with analysts forecasting earnings of $0.43 per share. The company's stock recently traded at $4.32, marking a 3.1% decline, and holds a "Hold" consensus rating. Recent …

ORMP | Oramed Pharmaceuticals Inc. Executive Compensation

This article provides an overview of Oramed Pharmaceuticals Inc. (ORMP), focusing on executive compensation, insider trading, and institutional holdings. It notes that executive compensation details are pending, with no recent insider trading activity reported for the ticker. The company is engaged in the research …

ORMP Q2'26 Earnings: revenue estimate is 0 USD

Oramed Pharmaceuticals Inc. (ORMP) is scheduled to announce its Q2'26 results on August 12. The company's revenue estimate for the quarter is $0, with an anticipated EPS of $0.43. This information is provided by FactSet Research Systems Inc.

Oramed Pharmaceuticals announces annual shareholder meeting

Oramed Pharmaceuticals will hold its 2026 annual stockholders meeting in Jerusalem on September 15, 2026. Shareholders will vote on the election of six directors, the ratification of Kesselman & Kesselman as the independent auditor, and a proposal to increase the 2019 long-term incentive plan …

ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026)

This article reports on an ARS SEC filing by ORAMED PHARMACEUTICALS INC. (ORMP) on August 3, 2026. The filing was accepted by the SEC EDGAR system at 04:06 PM on the same day. It provides company overview, stock rankings, latest news, and recent SEC …

Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Oramed Pharmaceuticals Inc (ORMP), focusing on its support and resistance levels, key indicators, and moving averages. As of July 30, 2026, the stock's price momentum score is 4.06, ranking 299 in its industry, and it is currently …

ORMP|Oramed Pharmaceuticals Inc|Price:4.050|Chg%:-0.070

Oramed Pharmaceuticals Inc. (ORMP) shows relatively healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The company is engaged in developing oral dosage forms for biological insulin and other proteins, leveraging its Protein Oral …

Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oramed Pharmaceuticals Inc (ORMP), highlighting its current valuation score of 8.93 within the Biotechnology & Medical Research industry. It notes the current P/E ratio is 1.56, significantly below its recent high and above its recent low. The …

Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence

Oramed Pharmaceuticals Inc (ORMP) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 21.30% quarter-over-quarter, now standing at 28.15%. James Simons is noted as the largest institutional …

Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Oramed Pharmaceuticals Inc (ORMP), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 3.61 and a beta value of 1.26, indicating higher volatility compared to the S&P 500. Key metrics …

Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Oramed Pharmaceuticals Inc (ORMP) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent payouts. The article primarily functions …

ORMP Q4 2025 Earnings: EPS Surges Past Estimates Despite Revenue Absence, Stock Declines 3.13% - Earnings Forecast Report

Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) generated $2.00 million USD in revenue last year, primarily from its Pharmaceutical Solutions segment. This marks an increase from $1.34 million USD in the previous year. The majority of this revenue, $2.00 million USD, originated from Israel.

ORMP|Oramed Pharmaceuticals Inc|Price:4.030|Chg%:-0.130

This article provides a comprehensive stock analysis of Oramed Pharmaceuticals Inc (ORMP), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows significant strengths, including steady revenue growth …

Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback

Oramed Pharmaceuticals (ORMP) stock is reflecting a strategic pivot following the discontinuation of its oral insulin program for type 2 diabetes due to insufficient efficacy. The company, a small-cap clinical-stage biotech, is now focusing its oral drug delivery technology on other indications such as …

Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP)

Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential

ORAMED PHARMACEUTICALS INC. SEC 10-Q Report

ORAMED PHARMACEUTICALS INC. Releases Q2 2024 10-Q Report

Oramed Pharmaceuticals Inc. Releases 2023 10-K Report Highlighting Financial Turnaround and Strategic Initiatives